Some of Thursday's midday movers:» Read More
Amgen, Budweiser, Disney and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
In this feature CNBC Contributor Herb Greenberg takes down the traders over their picks. Click here to find out which hot stock has Herb and Jeff Macke in opposite corners.
Another setback for Amgen anemia-drug franchise sent shares of the No. 1 biotechnology company spiraling down as much as 6.6% on Tuesday -- to a 2-1/2-year low -- as more analysts cut their ratings on the beaten-down stock.
Sometimes the stocks that trade on hope lead only to despair. Investors in biotech companies Amgen (AMGN) and Dendreon (DNDN) suffered serious side effects this week as the FDA raised questions about the safety and effectiveness of their flagship drugs. Is there any hope for a sector that trades on hope?
The U.S. Supreme Court said it would not hear an appeal by drug maker Amgen that centers on how much leeway appeals courts should have in overruling the findings of lower courts in patent cases.
Stocks are looking for direction amid a flurry of takeover headlines this morning. Asian stocks were higher overnight on the back of Wall Street's Friday gains, but European markets are mostly weaker.
Stocks ended broadly higher after new economic data raised hopes of a Fed rate cut, and investors were quick to jump back into the market following recent declines. "I'm not surprised to see the market snap back," said Alec Young, market strategist at S&P Equity Research. "The market was kind of overbought -- it was an excellent opportunity for a shakeout."
Several investment banks slashed their ratings on Amgen shares following the disclosure that a U.S. advisory panel called for marketing restrictions on popular anemia drugs sold by Amgen and Johnson & Johnson.
M&A news and analyst actions were some of the catalysts behind the most actively traded stocks on Friday.
Stocks will take their direction from economic data today after yesterday's drenching from negative April chain store sales took the Dow down 147 points and bit 1.7% off the Nasdaq and 1.4% off the S&P 500. European markets are lower, following overnight weakness in Asian markets.
The guys go behind the headlines and give you their take on ... JetBlue's CEO being forced out ... the latest company to miss earnings over milk prices ... and more.
Stocks sold off across the board, and the Dow fell almost 150 points, after mixed economic data prompted investors to book gains. "A day like today was inevitable," said Michael Cuggino of Permanent Portfolio Funds. "I would caution investors not to get overly concerned based on today's (economic) statistics."
Shares of Amgen and Johnson & Johnson traded lower after a U.S. advisory panel called for marketing restrictions on the companies' popular anemia drugs.
While I'm watching the webcast of the FDA Advisory Committee Meeting on the anemia drugs (Amgen, Johnson & Johnson), I wanted to hop on my TV versus print soapbox one more time.As I posted yesterday, I had asked a Dendreon spokeswoman for an interview with CEO Dr. Mitchell Gold in the wake of the FDA sending the company an "approvable letter" for its prostate cancer treatment Provenge.
U.S. Food and Drug Administration staffers on Tuesday expressed continued caution over the use of anemia drugs sold by Amgen and Johnson & Johnson , according to an agency document released on Tuesday.
Sears, Bank of New York, Amgen and more...Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
Actor Jonathan Tucker maintains his lead and fellow actor Stephen Collins holds on to second. Stephen was by far the most active celeb Tuesday (trust me, putting in all those ticker symbols for him was NOT easy), but his purchases could give him the lead if they perform well on Wednesday. Meanwhile, James Cromwell holds on to 3rd place, but Ernie Hudson falls from 4th place to 5th.
Actor Jonathan Tucker holds on to the top spot with a total portfolio value of $1,168,185.00 up $6,310.00 or 0.54% from Friday's total. But the real big news came from fellow actor Ernie Hudson. He climbed from 9th place on Friday to 4th Monday with a total portfolio value of $1,079,649.52--up $48,701.76 or 4.72% from Friday's total. Ernie added $45,701.76 to his total on the sale of Arch Coal (ACI) which was up 4.43% Monday.
Amgen, the world's largest biotechnology company, reported higher first-quarter profit on Monday, driven by increased sales of its anemia and arthritis drugs. Excluding items, the Thousand Oaks, Calif.-based company earned $1.08 a share, matching analysts' average forecast of $1.08 a share, according to Thomson Financial.
Amgen fools us: One of my favorite exercises at the Breaking News Desk is to figure out whether something is news, and how it might move the stock involved. This morning, a headline moved regarding Amgen’s anemia drug Aranesp. I’m not a pharmaceutical expert -- that’s why we have reporter Mike Huckman -- but since it involved a very large company and a drug I’d actually heard of, we knew it was news. Here’s where it got interesting...